New weight loss drug faces critical heart safety check
NCT ID NCT07229157
Summary
This early-stage study aims to check if an experimental drug called maridebart cafraglutide affects heart rhythm in people with overweight or obesity. It will involve 81 healthy adults to see if the drug is safe for the heart before larger studies can test if it helps with weight management. The main goal is to measure any changes in the heart's electrical activity, which is a standard safety step for new medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4968, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
Conditions
Explore the condition pages connected to this study.